Guardian Pharmacy Services (NYSE:GRDN) Stock Price Expected to Rise, Oppenheimer Analyst Says

Guardian Pharmacy Services (NYSE:GRDN) had its price target upped by investment analysts at Oppenheimer from $38.00 to $43.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Oppenheimer’s target price would suggest a potential upside of 17.49% from the stock’s current price.

Other analysts also recently issued reports about the stock. Stephens increased their price target on shares of Guardian Pharmacy Services from $35.00 to $36.00 and gave the company an “overweight” rating in a research report on Wednesday, January 14th. Zacks Research raised shares of Guardian Pharmacy Services from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, March 18th. Weiss Ratings reissued a “hold (c+)” rating on shares of Guardian Pharmacy Services in a report on Friday, March 27th. Bank of America assumed coverage on Guardian Pharmacy Services in a research note on Monday, April 27th. They set a “buy” rating and a $42.00 price objective on the stock. Finally, Truist Financial boosted their target price on Guardian Pharmacy Services from $38.00 to $43.00 and gave the company a “buy” rating in a research note on Monday, April 13th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $41.33.

Guardian Pharmacy Services Stock Performance

GRDN opened at $36.60 on Thursday. The company has a fifty day moving average price of $36.00 and a two-hundred day moving average price of $32.20. The firm has a market capitalization of $2.32 billion, a PE ratio of 47.53, a P/E/G ratio of 2.47 and a beta of 0.09. Guardian Pharmacy Services has a 52 week low of $19.17 and a 52 week high of $41.36.

Guardian Pharmacy Services (NYSE:GRDN) last posted its quarterly earnings results on Wednesday, March 11th. The company reported $0.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.10. The business had revenue of $397.62 million for the quarter, compared to analyst estimates of $390.04 million. Guardian Pharmacy Services had a return on equity of 31.64% and a net margin of 3.40%.Guardian Pharmacy Services’s quarterly revenue was up 17.4% compared to the same quarter last year. Equities analysts forecast that Guardian Pharmacy Services will post 1.17 EPS for the current year.

Insiders Place Their Bets

In other news, insider David K. Morris sold 187,855 shares of the company’s stock in a transaction dated Friday, March 20th. The stock was sold at an average price of $29.68, for a total transaction of $5,575,536.40. Following the completion of the transaction, the insider directly owned 254,472 shares of the company’s stock, valued at $7,552,728.96. This represents a 42.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director John Ackerman sold 1,103,364 shares of the stock in a transaction dated Friday, March 20th. The stock was sold at an average price of $29.68, for a total value of $32,747,843.52. Following the transaction, the director owned 345,123 shares of the company’s stock, valued at approximately $10,243,250.64. The trade was a 76.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 9,726,405 shares of company stock worth $288,679,700 in the last ninety days. 32.96% of the stock is owned by insiders.

Institutional Trading of Guardian Pharmacy Services

Hedge funds and other institutional investors have recently made changes to their positions in the business. Rakuten Investment Management Inc. bought a new position in Guardian Pharmacy Services during the third quarter worth $433,000. CSM Advisors LLC increased its stake in shares of Guardian Pharmacy Services by 40.9% during the third quarter. CSM Advisors LLC now owns 135,665 shares of the company’s stock worth $3,559,000 after purchasing an additional 39,360 shares during the period. Aristotle Capital Boston LLC lifted its holdings in Guardian Pharmacy Services by 58.5% during the 3rd quarter. Aristotle Capital Boston LLC now owns 649,463 shares of the company’s stock worth $17,035,000 after purchasing an additional 239,790 shares during the last quarter. TimesSquare Capital Management LLC grew its holdings in Guardian Pharmacy Services by 5.6% in the 3rd quarter. TimesSquare Capital Management LLC now owns 860,173 shares of the company’s stock valued at $22,562,000 after buying an additional 45,950 shares in the last quarter. Finally, SG Americas Securities LLC increased its position in Guardian Pharmacy Services by 274.9% during the 4th quarter. SG Americas Securities LLC now owns 19,017 shares of the company’s stock worth $572,000 after buying an additional 13,945 shares during the period.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.